Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

735 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Novel In Vitro Model of the Bone Marrow Microenvironment in Acute Myeloid Leukemia Identifies CD44 and Focal Adhesion Kinase as Therapeutic Targets to Reverse Cell Adhesion-Mediated Drug Resistance.
Ladikou EE, Sharp K, Simoes FA, Jones JR, Burley T, Stott L, Vareli A, Kennedy E, Vause S, Chevassut T, Devi A, Ashworth I, Ross DM, Hartmann TN, Mitchell SA, Pepper CJ, Best G, Pepper AGS. Ladikou EE, et al. Among authors: hartmann tn. Cancers (Basel). 2025 Jan 3;17(1):135. doi: 10.3390/cancers17010135. Cancers (Basel). 2025. PMID: 39796762 Free PMC article.
Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia.
Bibikova E, Parsa S, Floren M, Law B, Clevenger T, Cheung J, De Jesus G, Burke K, Gulrajani M, Yamaguchi K, Do P, Dougherty B, Whitston D, Brock G, Munugalavadla V, Frigault MM, Hartmann TN, Byrd JC, Furman RR, Brown JR, Covey T, Mortlock A. Bibikova E, et al. Among authors: hartmann tn. Hematol Oncol. 2025 Jan;43(1):e70008. doi: 10.1002/hon.70008. Hematol Oncol. 2025. PMID: 39716442 Clinical Trial.
Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma.
Shoumariyeh K, Csernalabics B, Salimi Alizei E, Reinscheid M, Giese S, Ciminski K, Kochs G, Schwemmle M, Lang-Meli J, Maas M, Roehlen N, Karl V, Graeser A, Sogukpinar O, von Metzler I, Grathwohl D, Rasche L, Hebart H, Kull M, Emmerich F, Waller CF, Duyster J, Engelhardt M, Hartmann TN, Bengsch B, Boettler T, Neumann-Haefelin C, Hofmann M, Thimme R, Luxenburger H. Shoumariyeh K, et al. Among authors: hartmann tn. Vaccines (Basel). 2024 Nov 1;12(11):1249. doi: 10.3390/vaccines12111249. Vaccines (Basel). 2024. PMID: 39591152 Free PMC article.
Author Correction: A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma.
Ryl T, Afanasyeva E, Hartmann T, Schwermer M, Schneider M, Schröder C, Wagemanns M, Bister A, Kanber D, Steenpass L, Schramm K, Jones B, Jones DTW, Biewald E, Astrahantseff K, Hanenberg H, Rahmann S, Lohmann DR, Schramm A, Ketteler P. Ryl T, et al. Among authors: hartmann t. Commun Biol. 2024 Sep 11;7(1):1119. doi: 10.1038/s42003-024-06830-1. Commun Biol. 2024. PMID: 39261566 Free PMC article. No abstract available.
Targeting NLRP3 inhibits AML progression by inducing PERK/eIF2-mediated apoptosis.
Luciano M, Sieberer H, Krenn PW, Dang HH, Vetter J, Neuper T, Amend D, Blöchl C, Weichenberger CX, Eglseer A, Unger MS, Andosch A, Steiner P, Neureiter D, Bauer R, Hummer L, Tesanovic S, Binder S, Elmer DP, Strandt H, Schaller S, Strunk D, Pleyer L, Greil R, Winkler S, Hartmann TN, Schmidt-Arras D, Huber CG, Aberger F, Horejs-Hoeck J. Luciano M, et al. Among authors: hartmann tn. Cell Commun Signal. 2024 Sep 2;22(1):424. doi: 10.1186/s12964-024-01777-6. Cell Commun Signal. 2024. PMID: 39223663 Free PMC article.
735 results